<DOC>
	<DOCNO>NCT00547001</DOCNO>
	<brief_summary>This study evaluate whether difference proportion woman report worsen severity hot flash three taper schedule one accept HT/ET regimen . Secondarily , hope evaluate whether difference frequency ( number occurrence per week ) , severity ( defined subjective scale mild , moderate , severe ) , `` Severity Index '' ( SI , equal product ) hot flash three taper schedule one accept HT/ET regimen .</brief_summary>
	<brief_title>Comparison Hormonal Therapy : Mediating Hot Flashes Tapering Regimens Mediating Hot Flashes</brief_title>
	<detailed_description>A Comparison Hormonal Therapy : Tapering Regimens Mediating Hot Flashes Clinicians ask year whether taper dose HT would make difference frequency severity vasomotor symptom menopausal woman stop HT therapy . This planned randomized , placebo-controlled trial ( RCT ) seek evaluate whether difference proportion woman report worsen severity hot flash three taper schedule one accept HT/ET regimen . Secondarily , hope evaluate whether difference frequency ( number occurrence per week ) , severity ( defined subjective scale mild , moderate , severe ) , `` Severity Index '' ( SI , equal product ) hot flash three taper schedule one accept HT/ET regimen . All participant randomize one three arm ( taper arm , placebo arm , `` cold turkey '' arm ) . Each patient 's gynecologist aware patient 's involvement study assist provide baseline safety information . All patient take current HT/ET regimen place study medication ( 1 mg Estradiol PO every day 8 week , `` stabilization '' phase ) . After 8-week stabilization period , participant begin therapy corresponding arm randomize . Each patient taper placebo arm take one capsule per day . The patient `` cold turkey '' arm discontinue acutely stabilization . The patient keep diary number frequency symptom study . Patients contact phone confirm complete diary develop side effect complication could force discontinuation study . Patients follow several additional week , discontinuation treatment placebo , monitor symptom . At end study , coordinator contact patient assure Medroxyprogesterone acetate , MPA , take properly woman uterus . They also confirm symptom , complication , question arise . At time , able return prior therapy deem appropriate physician . Patients recruit invitation upon present care physician . With invitation recruitment , patient give study form . Reasons ineligibility refusal note . After express interest , physician practice record sign form acknowledge patient annual physical exam ( include pelvic exam ) within last 12 month mammogram report negative ( BIRADS I II ) within last 24 month . An appointment make one study personnel coordinator . The patient bring sign form visit . At enrollment / consent visit , eligibility criterion review . All patient sign inform consent , randomize group .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Female . age 3570 , inclusive . Postmenopausal ( Natural surgical : see definition ) . Currently HT/ET least 6 month vasomotor symptomatology . Vasomotor symptom currently control medication . An annual physical &amp; pelvic exam perform within last 12mo The patient normal mammogram ( BIRADS I/II ) within last 24mo Males Hypertension , define either SBP &gt; 140 mmHg DBP &gt; 90 mmHg Lack compliance ( willingness adhere protocol ) Inability unwillingness swallow pill Patients contraindication HT/ET</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Hot flash</keyword>
	<keyword>vasomotor symptom</keyword>
	<keyword>taper regimen</keyword>
	<keyword>hormonal therapy</keyword>
	<keyword>Other menopausal symptom include mood change</keyword>
</DOC>